Clinical evaluation of rituximab treatment for neuromyelitis optica

Clinical evaluation of rituximab treatment for neuromyelitis optica

Introduction: Neuromyelitis optica is an inflammatory and usually relapsing demyelinating autoimmune disease of the central nervous system that targets the optic nerves and spinal cord. Rituximab has been used for different neurological diseases that are probably immune-mediated or involving humoral...

Full description

Bibliographic Details
Main Authors:	M.J. Fernández-Megía, B. Casanova-Estruch, F. Pérez-Miralles, J. Ruiz-Ramos, C. Alcalá-Vicente, J.L. Poveda-Andrés
Format:	Article
Language:	English
Published:	Elsevier España 2015-10-01
Series:	Neurología (English Edition)
Online Access:	http://www.sciencedirect.com/science/article/pii/S2173580815001212

Similar Items

Evaluación del uso de rituximab en la neuromielitis óptica
by: M.J. Fernández-Megía, et al.
Published: (2015-10-01)

Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
by: Fulin Gao, et al.
Published: (2019-03-01)

Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence
by: Masoud Etemadifar, et al.
Published: (2017-01-01)

The effect of intravenous immunoglobulin on neuromyelitis optica
by: M.J. Magraner, et al.
Published: (2013-03-01)

Should tocilizumab be the first line treatment for neuromyelitis optica together with rituximab?
by: R. Sawaya, et al.
Published: (2021-10-01)

An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica
by: Nicolas Collongues, et al.
Published: (2016-05-01)

Efficacy of Low-Dose Rituximab on Neuromyelitis Optica-Associated Optic Neuritis
by: Shuo Zhao, et al.
Published: (2021-05-01)

Neuromyelitis optica
by: Jacob Anu, et al.
Published: (2007-01-01)

Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study
by: Cimbora, D., et al.
Published: (2022)

The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab
by: Philippe Nicolas, et al.
Published: (2019-11-01)

Prognosis of Relapsing Neuromyelitis Optica
by: J Gordon Millichap
Published: (2003-03-01)

Treatment strategies for neuromyelitis optica
by: Tzu-Lun Huang, et al.
Published: (2018-01-01)

Changes in B and T-cell subsets and NMO-IgG/AQP-4 levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica
by: C. de Andrés, et al.
Published: (2015-06-01)

MRI in neuromyelitis optica
by: Shu⁃guang CHU, et al.
Published: (2012-04-01)

Pregnancy and neuromyelitis optica
by: Qiu-ying MA, et al.
Published: (2016-10-01)

Immunotherapy of Neuromyelitis Optica
by: Benjamin Bienia, et al.
Published: (2013-01-01)

The efficacy of rituximab in the therapy of neuromyelitis optica in a patient with Sjogren's syndrome: case-report and literature review
by: A V Torgashina, et al.
Published: (2018-05-01)

Efficacy and Safety of Rituximab in patients with Neuromyelitis Optica Spectrum Disorders: A prospective observation in Iranian Cases.
by: Maral Seyed Ahadi, et al.
Published: (2020-03-01)

Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study
by: Maral Seyed Ahadi, et al.
Published: (2021-07-01)

Myasthenia Gravis and Neuromyelitis Optica Association
by: J Gordon Millichap
Published: (2012-06-01)

Clinical and brain MRI appearances in neuromyelitis optica
by: Shijuan ZHANG, et al.
Published: (2011-06-01)

Neuromyelitis optica: Association with paroxysmal painful tonic spasms
by: E. Carnero Contentti, et al.
Published: (2016-10-01)

Treatment of Neuromyelitis Optica Spectrum Disorders
by: Koon-Ho Chan, et al.
Published: (2021-08-01)

Neuromyelitis optica pathogenesis and aquaporin 4
by: Kerr Douglas, et al.
Published: (2008-05-01)

Neuromyelitis Optica. Case Report
by: Patricia Quintero Cusguen, et al.
Published: (2009-04-01)

Multisystem involvement in neuromyelitis optica
by: Megan M Langille, et al.
Published: (2015-01-01)

Progress in diagnosis of neuromyelitis optica
by: Xiao⁃nan ZHONG, et al.
Published: (2012-04-01)

Autoantibodies in patients with neuromyelitis optica
by: Xin FAN, et al.
Published: (2016-10-01)

Paroxysmal dystonia and neuromyelitis optica
by: Felipe R. Schmidt, et al.
Published: (2012-04-01)

Neuromyelitis optica: Devic′s disease
by: Ajit Joshi, et al.
Published: (2015-01-01)

Atypical presentations of neuromyelitis optica
by: Douglas Sato, et al.
Published: (2011-10-01)

Molecular Pathogenesis of Neuromyelitis Optica
by: Simon A Broadley, et al.
Published: (2012-10-01)

Neuromyelitis optica: An anesthetic challenge
by: Kalyani Manasa Rapeti, et al.
Published: (2021-01-01)

Neuromyelitis Optica: Case Report
by: Deniz Tuncel, et al.
Published: (2008-06-01)

Neuromyelitis Optica Lesion Mimicking Brainstem Glioma
by: J Gordon Millichap
Published: (2007-12-01)

Retrospective Observation of Low-Dose Rituximab Treatment in Chinese Patients With Neuromyelitis Optica Spectrum Disorders in a Real-World Setting
by: Haibing Xiao, et al.
Published: (2020-07-01)

Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders
by: Xueli Fan, et al.
Published: (2016-01-01)

Recurrent acute rhombencephalomyelitis in an adult or neuromyelitis optica? Presentation of a case
by: J.M. García Domínguez, et al.
Published: (2012-04-01)

Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder
by: Meca-Lallana JE, et al.
Published: (2021-04-01)

Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis.
by: Saharat Aungsumart, et al.
Published: (2020-01-01)